Research & Development
Sanofi secures US approval for first treatment targeting neurological symptoms of Type 3 Gaucher disease
19 November 2026 -

French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced late Wednesday that it has received US Food and Drug Administration (FDA) approval for Infilbray (venglustat), an oral medicine for treating neurological manifestations of Type 3 Gaucher disease (GD3) in adults and children weighing at least 15 kg.

The once-daily glucosylceramide synthase inhibitor is designed to cross the blood-brain barrier and address neurological complications associated with the rare genetic disorder.

This approval is supported by positive results from the Phase 3 LEAP2MONO study, which demonstrated statistically significant superiority over enzyme replacement therapy imiglucerase across multiple neurological endpoints. Patients receiving Infilbray showed improvements in cognitive function, coordination and balance after 52 weeks of treatment.

Infilbray has received breakthrough therapy, rare paediatric disease and fast-track designations in the US, alongside orphan drug designations in the US, EU and Japan. Sanofi is pursuing further regulatory approvals, with applications planned across additional markets in 2026 and 2027. The medicine remains under regulatory review in the EU, Japan and other jurisdictions.

Login
Username:

Password: